Creative Med Technology Hldgs Stock Price, News & Analysis

Creative Medical Technology Holdings (NASDAQ: CELZ) entered agreements for immediate exercise of warrants to purchase 1,116,136 shares at an exercise price of $3.75 per share, generating approximately $4.2 million gross proceeds before advisory fees. The shares issuable upon exercise are registered on Form S-3.

In consideration, the company will issue new unregistered warrants exercisable for up to 2,790,340 shares at $3.75, subject to a post-issuance five-day VWAP reduction; new warrants will be exercisable for five years following shareholder approval. The company also agreed to reduce exercise prices on certain May 2022 warrants to $4.73. Transaction expected to close on or about October 29, 2025. Net proceeds intended for working capital and general corporate purposes.

Creative Medical Technology Holdings (NASDAQ: CELZ) issued a shareholder letter outlining clinical, IP, and AI milestones that frame near-term catalysts for 2026. The company is advancing two FDA-cleared programs: CELZ-201-DDT (ADAPT) for degenerative disc disease with FDA Fast Track and topline results expected in H1 2026, and CELZ-201 (CREATE-1) for new-onset Type 1 Diabetes with early data expected in 2026. The firm reports > 6 billion cGMP clinical-grade AlloStem cells manufactured, an IP portfolio of > 60 patents/pending, and two U.S. patents issued in Q3 2025 (Type 1 Diabetes exp. 2043; Heart Failure exp. 2042). The company highlights AI integration for iPScelz and emphasizes capital discipline while targeting scalable commercialization paths.

Creative Medical (NASDAQ: CELZ) announced receipt of two U.S. patents for its ImmCelz™ regulatory T cell platform and congratulated the 2025 Nobel laureates for Treg discoveries. The company named U.S. Patent 12931925B2 (expires 2043-05-24) for prevention/treatment of Type 1 diabetes via myeloid suppressor cell augmentation, and U.S. Patent 12385011B2 (expires 2042-12-15) for treating heart failure and post-infarct remodeling using ex vivo reprogrammed immune cells. Creative Medical said ImmCelz™ uses "supercharged" regulatory T cells, is being evaluated in the ongoing CREATE-1 clinical trial, and targets a U.S. treatable heart failure population of over 5 million and >b>6 million refractory angina candidates.

The release positions these patents as IP protection through 2042–2043 and highlights the company’s aim to translate Treg biology into regenerative immunotherapies.

Creative Medical Technology Holdings (NASDAQ: CELZ) has received FDA Fast Track designation for CELZ-201-DDT, its lead therapy targeting degenerative disc disease (DDD) and chronic lower back pain. The designation enables accelerated FDA interactions, rolling BLA submissions, and priority review eligibility.

CELZ-201-DDT, part of the AlloStem® platform, is an allogeneic perinatal cell therapy administered through minimally invasive intramuscular injections. The therapy has shown promising safety data and early efficacy signs in clinical trials. The global spinal disorders treatment market is projected to exceed $20 billion by 2030.

Creative Medical Technology (NASDAQ: CELZ) has received a Notice of Allowance from the USPTO for a patent application focused on treating Type 1 Diabetes using cell-based immunotherapy. The patent, effective until at least 2040, covers the use of the Company's ImmCelzTM product, which utilizes supercharged T regulatory cells with proprietary cell-free solutions.

The technology has been validated using cells from Type 1 Diabetes patients and aims to address the autoimmune condition where the body attacks insulin-producing beta cells. The patent allowance aligns with the Company's ongoing CREATE-1 clinical trial and strengthens their intellectual property portfolio in regenerative medicine.

Creative Medical Technology (NASDAQ: CELZ) has received a Notice of Allowance from the USPTO for a patent application covering their ImmCelz™ treatment for heart failure and post-infarct pathological remodeling. The patent, effective until at least 2040, will protect the company's proprietary treatment delivered through an ultra-minimally invasive outpatient procedure.

The potential market is significant, with over 5 million heart failure patients in the United States and an additional 6 million patients with chronic chest pain who could benefit from the treatment. The patent strengthens Creative Medical's intellectual property portfolio in regenerative medicine and cell-based therapies.

Creative Medical Technology Holdings (NASDAQ: CELZ) has received FDA clearance for expanded dose escalation in its Phase 1/2 trial of StemSpine® using AlloStem™ (CELZ-201-DDT), a cell therapy for chronic lower back pain caused by degenerative disc disease.

The trial's interim blinded data shows statistically significant pain reduction and improved mobility among participants. Key highlights include:

• No dose-limiting toxicities or serious adverse events reported at trial's halfway point
• Study employs minimally invasive ultrasound-guided injection with 4:1 treatment-to-placebo ratio
• Both Data Safety Monitoring Board (DSMB) and Institutional Review Board (IRB) have approved the new dosing strategy

The company reports enrollment remains on track, with final data expected to inform future clinical and regulatory strategies, potentially accelerating the pathway toward a pivotal Phase 3 trial for Biologics License Application (BLA) submission.

Creative Medical Technology Holdings (NASDAQ: CELZ) has secured agreements for the immediate exercise of warrants, generating approximately $3.7 million in gross proceeds. The agreement involves existing warrant holders purchasing 837,104 shares at $4.42 per share, with these shares already registered under Form S-1.

In exchange for the immediate cash exercise, CELZ will issue new unregistered warrants for up to 1,674,208 shares at an exercise price of $3.75 per share, exercisable for five years following shareholder approval. The transaction, with Roth Capital Partners as financial advisor, is expected to close around March 6, 2025.

The company plans to use the net proceeds for working capital and general corporate purposes. The new warrants are offered through private placement and will require SEC registration for resale of the underlying shares.

Creative Medical Technology Holdings (NASDAQ: CELZ) supports President Donald J. Trump’s executive order to expand access to in vitro fertilization (IVF). This aligns with their OvaStem® program, which has shown an 85% improvement in hormonal function and a 70% success rate in delivering healthy babies using a patient’s own eggs, with no safety concerns up to five years post-treatment. OvaStem® offers a novel alternative to traditional IVF by using a patient’s own cells, particularly benefiting those with Primary Ovarian Insufficiency (POI), who typically face a 5-10% chance of spontaneous pregnancy.

OvaStem® integrates the company's AlloStem® platform, already in two FDA-cleared U.S. clinical trials. Creative Medical Technology Holdings has also filed for Orphan Drug Designation for POI. The executive order, signed on February 18, 2025, mandates recommendations within 90 days to lower IVF costs, currently ranging from $12,000 to $25,000 per cycle. This initiative aims to make advanced fertility technologies more accessible.

CEO Timothy Warbington and Clinical Operations Director Courtney Bartlett emphasized the company’s commitment to providing safe, effective, and affordable infertility solutions. The company continues to advance its portfolio of regenerative medicine technologies to empower families and drive shareholder value.